Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
GUIDELINE MANAGEMENT AND PREVENTION OF OPIOID RELATED CONSTIPATION Applicable to: MidCentral Health, Medical Wards & AT&R Wards 1. Issued by: Medical Services Contact: Medical Staff PURPOSE Guidance on the management and prevention of opioid related constipation in medical patients. This guideline has been developed in association with MDHB Opioid Collaborative with the objective of reducing opioid related harm to patients. This guideline may also be used in other circumstances even with patients that are not on opioid medications. 2. SCOPE Applies to relevant medical & nursing practitioners and nursing staff managing medical patients with opioid related constipation or other causes of constipation where appropriate. 3. ROLES & RESPONSIBILITIES Every attempt should be made to prevent and anticipate potential constipation related to use of opioid medications. For instance, co-prescribing as needed (PRN) or regular laxatives or aperients may be appropriate whenever prescribing opioids. Furthermore, non-pharmacological methods to prevent and manage constipation should also be considered where appropriate. A medical or nurse practitioner should assess patients before considering prescribing treatments outlined in flowchart below. Nursing staff may also administer pre-approved standing order laxatives or aperients within their scope of practice. Pre-existing medical conditions, comorbidities and drug interactions must also be considered in managing these patients. There is an expectation for ongoing monitoring of effect of prescribed medications. There is also an expectation that accurate documentation of bowel habit with appropriate language is practised. For instance, terminology that includes BNO for X days and use of Bristol stool chart type. 4. GUIDELINE Staff Health and Safety Appropriate equipment (gloves/aprons etc) should be worn when in contact with faecal material or when administering rectal preparations of aperients In event of uncertainty, consultation should be had with MDHB Infection Control services Document No: MDHB-7120 Prepared by: Medical Registrar & Pharmacist Authorised by: MAPC Page 1 of 6 Version: 1 Issue Date: 21/Apr/2016 D:\840942780.doc MidCentral District Health Board 2016. CONTROLLED DOCUMENT. The electronic version is the most up-to-date version. MDHB will NOT take any responsibility in case of any outdated paper copy being used and leading to any undesirable consequence. Printed 28/04/2017 8:54:00 p.m. Guideline for Management and Prevention of Opioid Related Constipation Initial management ALL patients that are prescribed regular opioids, co-prescribe regular Laxsol 1-2 tablets PO BD AND Docusate 120mg PO BD Non-pharmacological measures: Encourage adequate fluid intake, where appropriate Encourage mobility Consider Kiwi Crush – regular or PRN High fibre diet – fruit and vegetables Bowels open? YES Continue current management and monitoring. NB: see appendix 1 YES Continue current management and monitoring. Consider weaning Laxsachet as appropriate. BNO 24-48 hrs Add Bisacodyl 5mg 1-2 tablets PO nocte Other considerations: Review therapy – stopping/weaning opioids and laxatives when appropriate, and other medication that may contribute to constipation e.g. CCB, ondansetron, TCA, antipsychotics Check calcium levels, thyroid function BNO 48-72 hrs Add Lax-sachets 1-2 sachets, PO, BD to TDS Other differentials: Bowel obstruction Pseudo-obstruction Other bowel pathology Overflow constipation Bowels open? NO If faecal loading suspected perform PR examination Perform Abdominal X-ray Consider alternative diagnosis NO Is the rectum full? Bisacodyl 10mg suppository STAT (against rectum wall) and STAT glycerol suppository (into the faeces) YES NO Bowels open? YES Faecal loading? NO Give 2 x Microlax Enema STAT YES Faecal disimpaction protocol (unless otherwise contraindicated): Bowels open? Lax-sachet 8 sachets/24 hours (maximum 3 days) Continue monitoring NB: see appendix 1 YES YES Continue monitoring NB: see appendix 1 BNO > 6 hrs Give Fleet enema STAT NB: see red box Bowels open? NO Bowels open? Consider patient factors, if appropriate, give STAT PicoPrep NB: see appendix YES NO Seek further specialist opinion – general surgery vs. gastroenterology Continue monitoring NB: see appendix YES Bowels open? NO Please note * Two types of Fleet enema available: Fleet Mineral Oil Or Fleet Phosphate (see appendix) Fleet phosphate enema is not recommended in elderly or those with renal impairment due to potential electrolyte imbalances. Seek further professional opinion Document No: MDHB-7120 D:\840942780.doc Printed 28/04/2017 8:54:00 p.m. Page 2 of 6 Version: 1 Guideline for Management and Prevention of Opioid Related Constipation 5. DEFINITION CCB TCA BD TDS PRN PR STAT Calcium channel blocker Tricyclic antidepressant Twice a day (Latin: bis die) Three times a day (Latin: ter die sumendum) As and when necessary (Latin: pro re nata) Rectal examination Give at once or immediately (Latin: statim) 6. RELATED MDHB DOCUMENTS MDHB-4184 7. Pain, Acute: Pharmacological Management in Adults FURTHER INFORMATION / ASSISTANCE Clinical Pharmacist Opioid Collaborative Group 8. APPENDICES APPENDIX 1 Monitoring and laxative information 9. KEYWORDS Constipation, opioid Document No: MDHB-7120 D:\840942780.doc Printed 28/04/2017 8:54:00 p.m. Page 3 of 6 Version: 1 Guideline for Management and Prevention of Opioid Related Constipation APPENDIX 1 Monitoring All nursing staff should monitor, record and review patient’s bowel status during every shift and notify the medical practitioner overseeing the patient’s care if loose stools are observed or if a new step in the flow-diagram needs to be initiated. If a patient declines any treatments indicated in the guideline, nursing staff should notify practitioners overseeing the patient’s care. Medical practitioners should review the patient and consider appropriate alternative treatment options. It is expected that nursing staff and medical practitioner addresses patient concerns and provides information about the treatment as stipulated by the Code of Rights. All practitioners should monitor and review patient’s bowel status daily, and stop laxatives when appropriate. Oral Laxatives Bulk-forming laxatives such as psyllium husk or sterculia are not recommended for patients with opioid-induced constipation due to an increased risk of bowel obstruction, especially in patients that are immobile or have poor fluid intake. However these agents are considered first-line for general constipation alongside non-pharmacological measures. It may take 72 hours before laxative effect is seen. Laxative class Generic name (Brand name) Stool softeners Docusate sodium (Coloxyl®) Mechanism and expected onset of action Act as surfactants resulting in an increased penetration of fluid into the stool. 24 – 72 hours onset Stimulant Senna (Senokot®) Bisacodyl (Lax-tab®, Dulcolax®) Stool softener + Stimulant Osmotic Docusate + senna (Laxsol®) Lactulose syrup (Laevolac®) Document No: MDHB-7120 D:\840942780.doc Printed 28/04/2017 8:54:00 p.m. Direct stimulation of sensory nerve endings in colonic mucosa resulting in increased motility. Administration & Safety considerations Adverse effects: Infrequent Abdominal discomfort, colic, cramps. Often combined with a stimulant laxative for opioids-induced constipation. There is limited evidence of effectiveness when used alone. Adverse effects: Infrequent Abdominal pain, nausea, vomiting, dizziness. 6 – 12 hours onset See above See above A non-absorbable disaccharide that is broken down by colonic bacteria. The metabolites exert an osmotic effect in the colon, resulting in distention and stimulates Adverse effects: Page 4 of 6 Common Flatulence, bloating Contraindicated in intestinal or bowel obstruction. Take each dose with a large glass of Version: 1 Guideline for Management and Prevention of Opioid Related Constipation peristalsis. 24 – 72 hours onset. Needs to be charted regular for maximal effect. Macrogol 3350 (Lax-Sachet®, Movicol®) A large polymer that exerts iso-osmotic activity with respect to normal intestinal contents, thus retaining water in the gut. 0.5 – 3 hours onset water. Requires adequate fluid to exert its pharmacological action. Avoid if poor fluid intake. Less effective in opioid-induced constipation, however this may be considered for constipation of other causes. Adverse effects: Common Abdominal distension and pain, nausea, flatulence Fluid and electrolyte disturbances may occur, monitor accordingly. Use with caution in patients with congestive heart failure and renal impairment. **Restricted medication on PHARMAC Hospital Medicines List** Refer to prescribing criteria on PHARMAC website. Requires Special Authority number for full subsidy in the community. Rectal Laxatives Laxative class Generic name (Brand name) Osmotic Glycerol suppository Stool Sodium citrate + sodium lauryl sulfoacetate + sorbitol enema (Microlax® 5mL) Phosphate enema (Fleet Phosphate® 133mL) Paraffin liquid Document No: MDHB-7120 D:\840942780.doc Printed 28/04/2017 8:54:00 p.m. Mechanism and expected onset of action A non-absorbable sugar, draws water into the stool. It has lubricating effects as well as stimulant effects due to its local irritant effects. 5 – 30 minutes onset Non-absorbable salts exerts osmotic effects by retaining fluid in the colon and stimulates peristalsis. 2 – 30 minutes onset Softens and lubricates Page 5 of 6 Administration & Safety considerations Adverse effects: Infrequent Rectal discomfort Adverse effects: Serious fluid and electrolyte disturbance (hypocalcaemia, hyperphosphataemia and hyperkalaemia), nausea, bloating, rectal irritation. Fluid and electrolyte disturbances may occur, monitor accordingly. Use with caution in patients with congestive heart failure, renal impairment and in the elderly. Adverse effects: Infrequent Version: 1 Guideline for Management and Prevention of Opioid Related Constipation softener enema (Fleet Mineral Oil® 133mL) Stimulant Bisacodyl suppository (Laxsuppositories®, Ducolax®) stool to facilitate passing of motion. 2 – 15 minutes onset Direct stimulation of sensory nerve endings in colonic mucosa resulting in increased motility. Anal leakage, rectal irritation Adverse effects: Infrequent Rectal irritation, abdominal pain, nausea, vomiting, dizziness. 15 – 60 minutes onset Bowel-cleansing Preparations Generic name (Brand name) Mechanism and expected onset of action Administration & Safety considerations Macrogol-3350 (Klean-Prep®) A large polymer that exerts iso-osmotic activity with respect to normal intestinal contents, thus retaining water in the gut. Adverse effects: NB: 1 Klean-Prep sachet ≈ 4 Lax-Sachets. Hence 2 KleanPrep ≈ 8 Lax-Sachets faecal disimpaction dose. Sodium picosulfate + magnesium oxide + citric acid (Pico-Prep®) 1 to 2 hours onset Broken down by colonic bacteria and metabolites exerts an osmotic effect and results in watery stool. 0.5 – 3 hours onset Document No: MDHB-7120 D:\840942780.doc Printed 28/04/2017 8:54:00 p.m. Page 6 of 6 Common Abdominal distension and pain, nausea, flatulence Fluid and electrolyte disturbances may occur, monitor accordingly. Use with caution in patients with congestive heart failure, renal impairment and the elderly. Elderly patients must receive adequate fluids during administration. Oral drugs should not be taken 1-hour before or after administration may be flushed from the gut thus absorption may be impaired. Version: 1